The litigation, initiated by a shareholder in August 2024, claims that the pharmaceutical firm misled the market by overstating the clinical and commercial potential of ARD-101. According to the complaint, the company's offering documents failed to accurately reflect the drug's safety profile, leading to artificially inflated investor expectations during the 15-month period in question. The plaintiff asserts that these omissions violated regulatory standards governing financial disclosures.
Aardvark Therapeutics Investors Face October Deadline in Securities Suit
Investors who poured more than $100,000 into Aardvark Therapeutics between February 2025 and May 2026 have until October 31 to join a pending class action lawsuit. The case centers on allegations that the company’s IPO documents and subsequent public disclosures contained material misrepresentations regarding the safety of its flagship drug, ARD-101.
Those impacted by the alleged stock price volatility are being advised by the Shareholders Foundation to review their legal options before the October deadline. The organization, which monitors portfolio litigation, emphasizes that it is not a law firm and provides this information as a public service to assist affected parties in navigating the securities class action process.
Comments (0)
No comments yet. Be the first!